GLP-1s · Retatrutide guide
Retatrutide for Beginners: What It Is and Why Everyone's Talking About It
Retatrutide is a triple agonist still in research. Learn how its three signals work, what studies reported, and why the FDA filing is planned for 2027.
There is a new name floating around: retatrutide.
It does not have a TV commercial. You cannot get it at the pharmacy. But in the research world, it is the name people are watching most closely. If you have heard the name and want to know what is different about it, here is the plain-English version.
The short version
- Retatrutide turns on three signals at once in one weekly injection.
- In the biggest study so far, the top dose averaged about 28% weight loss.
- Research also reported knee-pain relief and large improvements in liver fat.
- It is still in research. Its maker plans to file with the FDA in early 2027.
What retatrutide is
Retatrutide is a once-a-week injection that turns on three signals in your body at the same time. Scientists call it a triple agonist. Think of it as a medicine with three dials:
- GLP-1: the “I’m full” signal.
- GIP: a second gut hormone that helps the first one work.
- Glucagon: a signal tied to how much energy your body uses.
Tirzepatide, the medicine in Zepbound and Mounjaro, turns on two of those dials. Retatrutide is the first single molecule to turn on all three.
That is the basic difference. Retatrutide is not just another name for the same two-signal approach. It adds glucagon to the combination, which is why the research is getting so much attention.
Why the third dial matters
| Medicine | Signals |
|---|---|
| Semaglutide | GLP-1 |
| Tirzepatide | GLP-1 + GIP |
| Retatrutide | GLP-1 + GIP + Glucagon |
Picture your weight like a bathtub. Appetite is the faucet. Energy use is the drain.
Earlier medicines mostly turn down the faucet. They make you feel full sooner and stay full longer. Retatrutide does that too, while the glucagon signal also seems to open the drain a little by nudging the body to use more energy. Earlier research found that retatrutide reduced food intake and increased energy use.
That gives researchers another part of the equation to study. The point is not that one signal makes every other factor disappear. It is that the medicine is working across three signals at once, including one tied to energy use.
How the studies used it
In the studies, participants started at a low dose of 2 mg once a week. They stepped up every four weeks until they reached their target dose, such as 9 mg or 12 mg. That gradual step-up is part of the study design.
Those are study details, not a do-it-yourself schedule. Retatrutide remains in research, and it is not available at the pharmacy. The useful takeaway for now is what researchers are testing and what they have reported so far.
The results that made headlines
Retatrutide is being tested in a large late-stage research program that started in 2023. The first four studies alone enrolled more than 5,800 people. By mid-2026, the company had reported positive results across five late-stage studies.
The large obesity study
People with obesity took retatrutide for about a year and a half: 80 weeks. At the top dose, they lost an average of about 70 pounds, or 28% of their body weight.
Nearly half of the participants — about 45 out of 100 — lost 30% or more. That level of weight loss used to be associated mainly with weight-loss surgery.
Those numbers explain the buzz. They come from the study group and dose described above.
People with type 2 diabetes
Weight loss is often harder for this group. In a study of about 1,150 adults, average weight loss was about 13%, 19%, and 21% on the three doses, compared with about 4% on placebo. Average blood sugar improved too.
People with heart disease and severe obesity
In a study of nearly 1,950 adults, weight loss reached about 22% to 23% at the top doses, compared with about 3% on placebo.
People with knee arthritis
This result surprised a lot of people. In people with obesity and knee arthritis, the top dose led to about 29% weight loss over 68 weeks, and knee-pain scores dropped by up to about 75%.
People on placebo felt better too. That is common in pain studies. What matters is the gap: about seven in ten people on the two top doses had a big drop in pain, compared with about one in four on placebo.
For someone whose knee pain makes movement harder, that finding matters because the study looked at both weight and pain. It does not turn retatrutide into a knee treatment you can get today. It is one of the results researchers are following as the program continues.
Beyond the scale
Weight is the headline, but the early data points wider.
- Liver: In an earlier study of people with fatty liver disease, more than 90% of people at the top dose got their liver fat back into the normal range.
- Blood fats, blood pressure, and waist: In the heart-disease study, the top dose lowered blood fats by about 37%, blood pressure by about 9 points, and waist size by about 7.5 inches. An inflammation marker dropped by about half.
- Blood pressure in the knee study: The top dose lowered it by about 14 points.
Those are different measures from different study groups. The common thread is that researchers are watching more than the number on the scale. The next article in this series looks more closely at whole-body effects.
Where retatrutide stands today
Retatrutide is still in research. Eli Lilly, the company behind it, has said it plans to ask the FDA for approval in the first quarter of 2027. Studies are also continuing in other areas, including sleep apnea, chronic low-back pain, heart and kidney outcomes, and fatty liver disease.
An FDA filing is not the same thing as a launch date. Until then, you will hear about retatrutide in the news, not at the pharmacy counter. That is why it feels like everyone is talking about something nobody can get yet.
The big picture
Retatrutide combines three signals: GLP-1, GIP, and glucagon. It is taken once a week in studies, with a gradual step-up in dose. The biggest study so far reported about 28% average weight loss at the top dose. Studies also reported results for knee pain, liver fat, and other health measures.
The story is compelling, but the status is simple: retatrutide is still being studied. The FDA filing is planned for early 2027. That is the date to ask about a filing, not a date to expect a pharmacy prescription.
Quick answers
What does “triple agonist” mean?
One medicine switches on three signals: GLP-1, GIP, and glucagon.
How does it compare to Zepbound?
Retatrutide’s numbers are larger, but they come from different studies. It is not a direct head-to-head comparison.
When could it be available?
Its maker plans to file with the FDA in early 2027. A filing date is not a launch date.
If you want help making sense of what is available now and how weight, joint pain, movement, and your overall plan fit together, work with me. I work alongside your prescribing provider; I do not prescribe GLP-1 medicines.
Sources: [4] [5] [6] [7] [8] [14] [15] [24] [34]
Where to go next
With the trial numbers in hand, see what those effects mean for the whole body — and what triple agonism feels like week by week.